The Chennai-based pharma major, Orchid Chemicals & Pharmaceuticals Ltd. (Orchid) has been granted the Certificate of Suitability (CoS) certification by the European Directorate for Quality of Medicines (EDQM) for its API product Cefotaxime Sodium. This is the 6th CoS that has been granted to Orchid. A few weeks ago Orchid had approval for another API, Cefazolin Sodium.

According to company communication, "We now have six of our products approved by the EDQM, out of which four products are premium products with a good market size and potential. We are confident of an increased flow of revenue from the European region during the coming quarters," said K Raghavendra Rao, managing director, Orchid.

It is to be noted Orchid's sterile API product, Cefazolin was approved by the USFDA a few months ago and this was the first sterile product approval for Orchid. The company also had its fourth Certificate of Suitability (CoS) approval for another API Cefixime during the last quarter. Orchid has set up a state of the art manufacturing facility at Alathur near Chennai to manufacture API products.